NY-ESO-179-108

NY-ESO-179-108 is a synthetic peptide vaccine based on amino acids 79 to 108 of the NY-ESO-1 cancer-testis antigen, used as an immunotherapeutic agent. It is designed to stimulate a robust, integrated CD4+ and CD8+ T cell immune response against tumors expressing NY-ESO-1, often formulated with immune adjuvants such as CpG-B or administered in combination with Montanide ISA-51. Several phase I and II studies have investigated its potential in patients with advanced melanoma and other cancers, frequently as part of vaccination regimens to enhance anti-tumor immunity and, in some settings, combined with immune checkpoint inhibitors such as anti-PD-1 therapy[3][6][7][8][9]. The primary developer(s) and manufacturer(s) for this specific peptide vaccine have not been publicly specified in accessible trial documentation.

Other names

NY-ESO-1 79-108 peptideNY-ESO1 79-108 peptideNY-ESO 1 79-108 peptideNY-ESO-1:79-108NY-ESO-179-108 peptideNY-ESO179-108 peptideNY-ESO 179-108 peptide